Dror Bacher - DarioHealth Corp Chief Officer

DRIO Stock  USD 0.79  0.07  9.72%   

Executive

Mr. Dror Bacher serves as Chief Operating Officer of the company. Mr. Bacher previously served as our Vice President of Research and development as well as Vice President of Operations since 2013 where he worked on product development as well as building a scalable supply chain. Mr. Bacher has over 18 years of experience in various technological companies and his expertise includes product management, product development and business operations in multi disciplinary environments. Between 2008 and 2013, Mr. Bacher Served in several leadership roles at Amdocs Limited, including working as a part of the Chief Technology Office, managing enterprise development. programs for a variety of software products associated with service delivery, as well as serving as head of process Prior to Amdocs, Mr. Bacher served in a senior role at Tower Semiconductor, the global specialty foundry leader for IC manufacturing, where he was responsible for business operations and commercialization expansion since 2017.
Age 49
Tenure 7 years
Professional MarksMBA
Address 122 W 57th St,, New York, NY, United States, 10019
Phone972 477 0637 7
Webhttps://www.dariohealth.com
Bacher holds a B.Sc. in computer science and an MBA degree from Haifa University.

Dror Bacher Latest Insider Activity

Tracking and analyzing the buying and selling activities of Dror Bacher against DarioHealth Corp stock is an integral part of due diligence when investing in DarioHealth Corp. Dror Bacher insider activity provides valuable insight into whether DarioHealth Corp is net buyers or sellers over its current business cycle. Note, DarioHealth Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell DarioHealth Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

DarioHealth Corp Management Efficiency

The company has return on total asset (ROA) of (0.3474) % which means that it has lost $0.3474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7491) %, meaning that it created substantial loss on money invested by shareholders. DarioHealth Corp's management efficiency ratios could be used to measure how well DarioHealth Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -1.26. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, DarioHealth Corp's Intangibles To Total Assets are very stable compared to the past year. As of the 29th of November 2024, Debt To Assets is likely to grow to 0.31, while Other Current Assets are likely to drop about 1 M.
DarioHealth Corp currently holds 29.54 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. DarioHealth Corp has a current ratio of 6.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about DarioHealth Corp's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Daniella MehalikPsychemedics
34
Steven SpringmeyerBiodesix
N/A
Lisa MetznerRosasNeuronetics
N/A
Patrick KinneyPsychemedics
N/A
Shannon ShoemakerPsychemedics
38
Xiaozhi HuBurning Rock Biotech
N/A
Jessica OlbrichtBiodesix
N/A
Benjamin JDSera Prognostics
45
Rusty PageNeuronetics
N/A
Sara GrubbsNeuronetics
N/A
Austin AertsSera Prognostics
37
Hao LiuBurning Rock Biotech
50
Kieran OKaneBiodesix
47
Rick GrubbsNeuronetics
N/A
Cory AndersonNeuronetics
N/A
James MDBiodesix
N/A
John WegenerExagen Inc
55
MBA MSExagen Inc
45
Jeffrey BlackExagen Inc
55
Mark DeBlockBiodesix
N/A
Robbie LuntBiodesix
N/A
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York. Dario Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 200 people. DarioHealth Corp (DRIO) is traded on NASDAQ Exchange in USA. It is located in 122 W 57th St,, New York, NY, United States, 10019 and employs 276 people. DarioHealth Corp is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

DarioHealth Corp Leadership Team

Elected by the shareholders, the DarioHealth Corp's board of directors comprises two types of representatives: DarioHealth Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DarioHealth. The board's role is to monitor DarioHealth Corp's management team and ensure that shareholders' interests are well served. DarioHealth Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DarioHealth Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tomer BenKiki, Chief Officer
Zvi CPA, Treasurer CFO
Josh Fischer, Senior Compliance
Dov Oppenheim, CoFounder Chief
Brian Harrigan, Senior Sales
Richard Anderson, President
Claudia Levi, Content Manager
Jean Muyl, Head America
Zvi David, Treasurer CFO
Kat Parrella, Investor Manager
Dror Bacher, Chief Officer
Erez Raphael, Chairman, CEO and Pres
Mona Dean, Chief Officer
Mary Mooney, Vice Marketing
Limor Drezner, Chief Officer
Olivier Jarry, President and Chief Commercial Officer
Omar MD, Chief Officer

DarioHealth Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DarioHealth Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DarioHealth Corp

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DarioHealth Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DarioHealth Corp will appreciate offsetting losses from the drop in the long position's value.

Moving against DarioHealth Stock

  0.73GH Guardant HealthPairCorr
  0.64LH LaboratoryPairCorr
  0.57DXCM DexCom Inc Sell-off TrendPairCorr
  0.49VREX Varex Imaging CorpPairCorr
  0.43VEEV Veeva Systems Class Earnings Call This WeekPairCorr
The ability to find closely correlated positions to DarioHealth Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DarioHealth Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DarioHealth Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DarioHealth Corp to buy it.
The correlation of DarioHealth Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DarioHealth Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DarioHealth Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DarioHealth Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DarioHealth Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DarioHealth Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dariohealth Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dariohealth Corp Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DarioHealth Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in DarioHealth Stock, please use our How to Invest in DarioHealth Corp guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DarioHealth Corp. If investors know DarioHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DarioHealth Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.93)
Revenue Per Share
0.631
Quarterly Revenue Growth
1.11
Return On Assets
(0.35)
Return On Equity
(0.75)
The market value of DarioHealth Corp is measured differently than its book value, which is the value of DarioHealth that is recorded on the company's balance sheet. Investors also form their own opinion of DarioHealth Corp's value that differs from its market value or its book value, called intrinsic value, which is DarioHealth Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DarioHealth Corp's market value can be influenced by many factors that don't directly affect DarioHealth Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DarioHealth Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if DarioHealth Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DarioHealth Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.